Search PubMed⌕ Search

Biomedical subjects

F Simon

Publications and source records attributed to F Simon.

At least 199 records · Page 11Linked to original sources
PubMed1984

Contact lens fitting for binocular micromovement recording.

Specially designed hard contact lenses for binocular micromovement recording were tested under static and dynamic conditions. In order to overcome contact lens adherence in fitting 0.2 mm below mean keratometer reading, forces of 70 g were necessary (weight of contact lens 0.058 g). In dynamic testing of induced sinuswave and original micromovement on an experimental globe, pattern identity and synchronism of globe and contact lens are given. Closely spaced saccades were recorded without deformation. Difference in amplitude is due to detector irregularity. Computer calculated time difference in saccadic onset was below 0.003 s. Therefore, requirements are met for micromovement recording in clinical cases and the reliability is outlined.

Contact Lenses↗
PubMed1984

Binocular micromovement recording of human eyes:--methods.

An apparatus is described for binocular recording of micromovements of human eyes, with the contact lens mirror technique used frequently. Horizontal and vertical micromovements of both eyes are recorded simultaneously by means of instruments measuring light-spot positions. Spatial resolution of the measuring instrument is 12 s of arc, while the time resolution is 0.5 ms for this apparatus. The fixation mark (Snellen character) is at a distance of 5 m without any restrictions to the view. The micromovement data are registered by a microcomputer. A second computer enables precise calculation of the results which are given as multicoloured graphs (X/Y-, X/t-graph, velocity/t-graph, frequency analysis, phase correlation of both eyes). In this way the requirements are met for the clinical application of this measuring instrument on patients.

Contact Lenses↗
PubMed1978

Prognostic factors and treatment of multiple myeloma: interest of a cyclic sequential chemohormonotherapy combining cyclophosphamide, melphalan, and prednisone.

1. A type 2 therapeutic trial consisting of the administration of monthly cycles of chemohormonotherapy, each cycle combining weekly sequences of mephalan, prednisone, cyclophosphamide, and prednisone, has been achieved in 20 stage II or III myeloma patients. Tolerance of this regimen in treated out-patients was found to be excellent. Preliminary data indicate that the better survival rate in patients treated by this regimen is still not reached at a 30-month follow-up examination by three other nonrandomized control groups of patients receiving continuous therapy with prednisone alone, prednisone + cyclophosphamide, or prednisone + melphalan. 2. Analysis of the main prognostic factors of the four trials indicates that a) IgG-type myelomas are associated with a better prognosis than IgA type; nonexcreting myelomas are associated with the best prognosis, while Bence Jones myelomas are associated with a prognosis as poor as that of the IgA type; b) tumor volume as well as renal insufficiency, at the time of diagnosis, are also prognosis factors; this study confirms the prognostic value of the recently proposed clinical staging system based on these parameters but outlines that 10% of the patients died from a cause not directly related to myeloma plasmocyte proliferation. 3. In conclusion, these results point out: a) the possible advantage of using two alkylating agents instead of one at the beginning of the disease; b) the need to classify multiple myeloma according to prognosis before attempting therapeutic trials.

Adult↗